Comprehensive inhibition of PI3K-AKT-mTOR signalling with the combination of mTORC1/2 and PI3Kβ inhibitors is effective in DLBCL cell lines of different subtypes [8, 29]. This evidence concerns the gene PIK3CA and diffuse large B-cell lymphoma.